DK2552966T3 - Antistoffer mod csf-1r - Google Patents
Antistoffer mod csf-1r Download PDFInfo
- Publication number
- DK2552966T3 DK2552966T3 DK11713416.3T DK11713416T DK2552966T3 DK 2552966 T3 DK2552966 T3 DK 2552966T3 DK 11713416 T DK11713416 T DK 11713416T DK 2552966 T3 DK2552966 T3 DK 2552966T3
- Authority
- DK
- Denmark
- Prior art keywords
- ser
- leu
- val
- pro
- gly
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (16)
1. Antistof, der specifikt binder human CSF-1 R-variant (SEQ ID NO. 15), omfattende en tung kæde omfattende aminosyresekvensen SEQ ID NO:9 og en let kæde omfattende aminosyresekvensen SEQ ID NO:10.
2. Antistof, der specifikt binder human CSF-1 R (SEQ ID NO. 16), omfattende en tung kæde omfattende aminosyresekvensen SEQ ID NO:9 og en let kæde omfattende aminosyresekvensen SEQ ID NO:10.
3. Antistof ifølge krav 1 eller 2, omfattende to tunge kæder, som hver omfatter aminosyresekvensen SEQ ID NO:9, og to lette kæder, som hver omfatter aminosyresekvensen SEQ ID NO:10.
4. Farmaceutisk sammensætning omfattende antistoffet ifølge et hvilket som helst af kravene1-3 sammen med et farmaceutisk acceptabelt bærestof, fortyndingsmiddel eller hjælpestof.
5. Farmaceutisk sammensætning ifølge krav 4, yderligere omfattende et yderligere farmaceutisk middel.
6. Antistof ifølge et hvilket som helst af kravene 1-3 til anvendelse som et lægemiddel.
7. Antistof ifølge et hvilket som helst af kravene 1-3 til anvendelse ved behandling af cancer.
8. Antistof til anvendelse ifølge krav 7, hvor canceren er leukæmi, brystcancer, endometriecancer, prostatacancer, ovariecancer, kolorektal cancer, he-patocellulær cancer, renal cancer, myelomatose eller Hodgkins lymfom.
9. Antistof til anvendelse ifølge krav 8, hvor canceren er leukæmi, brystcancer, endometriecancer eller prostatacancer.
10. Antistof til anvendelse ifølge krav 9, hvor canceren er leukæmi, brystcancer eller prostatacancer.
11. Antistof til anvendelse ifølge krav 6-10, hvor antistoffet indgives før, under, i det væsentlige samtidig med, eller efter påbegyndelse af terapi med en anden anti-cancer-behandling.
12. Antistof til anvendelse ifølge krav 11, hvor anti-cancer-behandlingen er udvalgt fra gruppen bestående af et anti-angiogenese-middel, et kemoterapeutisk middel og et anti-neoplastisk middel.
13. Antistof til anvendelse ifølge krav 12, hvor det anti-neoplastiske middel er udvalgt fra gruppen bestående af docetaxel, paclitaxel, Herceptin® og doxorubicin.
14. Antistof til anvendelse ifølge et hvilket som helst af kravene 1-3 til anvendelse ved behandling af cancer hos en patient, omfattende måling af niveauet af CSF-1 i en prøve udtaget fra patienten, hvor prøven er udvalgt fra gruppen bestående af blod, serum, plasma, tumorceller og cirkulerende tumorceller, og indgivelse til patienten af antistoffet ifølge et hvilket som helst af kravene 1-3, hvis CSF-1-niveauerne er højere end CSF-1-niveauer fundet kos en kontrolpopulation.
15. Antistof ifølge et hvilket som helst af kravene 1-3 til anvendelse ved behandling af cancer hos en patient, omfattende måling af niveauet af IL-34 i en prøve udtaget fra patienten, hvor prøven er udvalgt fra gruppen bestående af blod, serum, plasma, tumorceller og cirkulerende tumorceller, og indgivelse til patienten af antistoffet ifølge et hvilket som helst af kravene 1-3, hvis IL-34-niveauerne er højere end IL-34-niveauer fundet hos en kontrolpopulation.
16. Fremgangsmåde til bestemmelse af, om et individ, som har en cancer, er kandidat til et anti-CSF-1 R-antistofbaseret cancerbehandlingsregime, hvor antistoffet er antistoffet ifølge et hvilket som helst af kravene 1-3, omfattende: ex vivo- eller in v/fro-bestemmelse af niveauet af CSF-1 eller IL-34 eller begge i en prøve fra individet, hvor prøven er udvalgt fra gruppen bestående af blod, serum, plasma, tumorceller og cirkulerende tumorceller, hvor en stigning i niveauet af CSF-1 eller IL-34 eller begge sammenlignet med niveauet af CSF-1 eller IL-34 eller begge hos et individ, der ikke lider af cancer, indikerer, at individet er kandidat til det anti-CSF-1 R-antistof-baserede cancerbehandlingsregime.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31989610P | 2010-04-01 | 2010-04-01 | |
| PCT/US2011/030148 WO2011123381A1 (en) | 2010-04-01 | 2011-03-28 | Antibodies against csf-1r |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2552966T3 true DK2552966T3 (da) | 2017-08-14 |
Family
ID=44010222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11713416.3T DK2552966T3 (da) | 2010-04-01 | 2011-03-28 | Antistoffer mod csf-1r |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8263079B2 (da) |
| EP (2) | EP3156419A1 (da) |
| JP (1) | JP5767310B2 (da) |
| KR (1) | KR101439719B1 (da) |
| CN (1) | CN102834414B (da) |
| AR (1) | AR080698A1 (da) |
| AU (1) | AU2011232850B2 (da) |
| BR (1) | BR112012024564A2 (da) |
| CA (1) | CA2795081C (da) |
| CY (1) | CY1119324T1 (da) |
| DK (1) | DK2552966T3 (da) |
| EA (1) | EA021600B1 (da) |
| ES (1) | ES2640909T3 (da) |
| HR (1) | HRP20171153T1 (da) |
| HU (1) | HUE036379T2 (da) |
| IL (1) | IL222222A (da) |
| JO (1) | JO3291B1 (da) |
| LT (1) | LT2552966T (da) |
| ME (1) | ME02806B (da) |
| MX (1) | MX2012011234A (da) |
| NZ (1) | NZ602621A (da) |
| PL (1) | PL2552966T3 (da) |
| PT (1) | PT2552966T (da) |
| RS (1) | RS56219B1 (da) |
| SG (1) | SG183829A1 (da) |
| SI (1) | SI2552966T1 (da) |
| TW (1) | TWI402078B (da) |
| UA (1) | UA111818C2 (da) |
| WO (1) | WO2011123381A1 (da) |
| ZA (1) | ZA201206926B (da) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| US10487148B2 (en) | 2010-01-28 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated impairments |
| US20160208011A1 (en) | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
| US10626399B2 (en) | 2010-01-28 | 2020-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3) |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| US9161968B2 (en) | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| KR20140127855A (ko) * | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| AR090263A1 (es) * | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| AR095882A1 (es) | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
| GB201315487D0 (en) | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| NZ720949A (en) | 2013-12-09 | 2019-03-29 | Univ Leland Stanford Junior | Methods and compositions for treating aging-associated conditions |
| US10905779B2 (en) | 2013-12-09 | 2021-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening human blood products comprising plasma using immunocompromised rodent models |
| KR102000224B1 (ko) * | 2014-02-03 | 2019-07-16 | 전대연 | 스마트 이메일 관리방법 |
| SG11201610672YA (en) | 2014-06-23 | 2017-01-27 | Five Prime Therapeutics Inc | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| EP3212670B1 (en) | 2014-10-29 | 2020-12-23 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
| MX2017008218A (es) | 2014-12-22 | 2017-10-18 | Five Prime Therapeutics Inc | Anticuerpos anti-csf1r para tratar pvns. |
| AU2016249981B2 (en) | 2015-04-13 | 2022-02-17 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
| JP6851322B2 (ja) | 2015-05-27 | 2021-03-31 | ユーシービー バイオファルマ エスアールエル | 神経疾患を治療する方法 |
| AU2016279804B2 (en) | 2015-06-15 | 2019-03-07 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated conditions |
| JP6621252B2 (ja) * | 2015-06-17 | 2019-12-18 | 国立大学法人北海道大学 | 治療耐性がんに対する治療耐性低減剤 |
| KR20180012873A (ko) * | 2015-06-24 | 2018-02-06 | 에프. 호프만-라 로슈 아게 | 림프종 또는 백혈병에서 림프구증가증의 유도에 사용하기 위한 인간 csf-1r에 대한 항체 |
| EP3108897A1 (en) * | 2015-06-24 | 2016-12-28 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias |
| CN108367070B (zh) | 2015-11-04 | 2022-10-28 | 杜克大学 | 免疫毒素与检查点抑制剂的组合治疗 |
| WO2017085566A1 (en) * | 2015-11-20 | 2017-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for increase/induction of immune responses |
| WO2017091429A1 (en) | 2015-11-24 | 2017-06-01 | Eli Lilly And Company | Combination therapy for cancer |
| PT3380615T (pt) * | 2015-11-25 | 2021-04-01 | Nogra Pharma Ltd | Oligonucleótidos antissentido il-34 e métodos de utilização dos mesmos |
| EP3995141B1 (en) | 2016-04-28 | 2024-01-03 | Alkahest, Inc. | Plasma fractions as therapy for thymic cancer |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| CN109790220A (zh) | 2016-08-25 | 2019-05-21 | 豪夫迈·罗氏有限公司 | 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药 |
| AR109770A1 (es) | 2016-10-18 | 2019-01-23 | Lilly Co Eli | ANTICUERPOS DEL RECEPTOR II DE TGF-b |
| EA039316B1 (ru) | 2016-10-24 | 2022-01-12 | Алкахест, Инк. | Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением |
| CN110072553B (zh) * | 2016-12-22 | 2023-09-15 | 豪夫迈·罗氏有限公司 | 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗 |
| WO2018144334A1 (en) | 2017-02-02 | 2018-08-09 | Imclone Llc | Dosing regimen for anti-csf-1r antibody |
| WO2018183366A1 (en) | 2017-03-28 | 2018-10-04 | Syndax Pharmaceuticals, Inc. | Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy |
| CN110709422B (zh) | 2017-04-19 | 2023-12-26 | 马伦戈治疗公司 | 多特异性分子及其用途 |
| US11040068B2 (en) | 2017-04-26 | 2021-06-22 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
| MX2019012795A (es) | 2017-04-26 | 2020-02-13 | Alkahest Inc | Régimen de dosificación para el tratamiento de deterioros cognitivos y motores con plasma de sangre y productos de plasma de sangre. |
| CN111278459A (zh) | 2017-05-19 | 2020-06-12 | 赛达克斯制药股份有限公司 | 组合疗法 |
| US11306144B2 (en) | 2017-08-25 | 2022-04-19 | Five Prime Therapeutics, Inc. | B7-H4 antibodies and methods of use thereof |
| EP3681535A1 (en) | 2017-09-13 | 2020-07-22 | Five Prime Therapeutics, Inc. | Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer |
| EP3720881A1 (en) * | 2017-12-08 | 2020-10-14 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| BR112020016986A2 (pt) | 2018-02-21 | 2021-03-02 | Five Prime Therapeutics, Inc. | formulações de anticorpo contra b7-h4 |
| GB201803226D0 (en) * | 2018-02-28 | 2018-04-11 | Ultrahuman Twelve Ltd | CSF1R Binding agents |
| KR20200144094A (ko) | 2018-03-02 | 2020-12-28 | 파이브 프라임 테라퓨틱스, 인크. | B7-h4 항체 및 이의 사용 방법 |
| PE20210313A1 (es) * | 2018-03-28 | 2021-02-12 | Bristol Myers Squibb Co | Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso |
| BR112020023746A2 (pt) * | 2018-05-23 | 2021-02-17 | Beigene, Ltd. | anticorpo, composição farmacêutica, método para tratar câncer, ácido nucleico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo e reagente de diagnóstico |
| CN108948200B (zh) * | 2018-07-18 | 2019-05-10 | 博奥信生物技术（南京）有限公司 | 一种抗人csf-1r单克隆抗体及其应用 |
| CN108948201B (zh) * | 2018-07-18 | 2019-05-07 | 博奥信生物技术（南京）有限公司 | 抗人csf-1r单克隆抗体及应用 |
| CN109096397B (zh) * | 2018-07-18 | 2019-04-16 | 博奥信生物技术（南京）有限公司 | 一种抗人csf-1r单克隆抗体及应用 |
| US12258398B2 (en) * | 2018-07-27 | 2025-03-25 | Alector Llc | Anti-Siglec-5 antibodies and methods of use thereof |
| CN113164777B (zh) | 2018-09-27 | 2024-12-13 | 马伦戈治疗公司 | Csf1r/ccr2多特异性抗体 |
| SG11202103696XA (en) | 2018-10-26 | 2021-05-28 | Alkahest Inc | Use of plasma and plasma fractions for improvement of pain, wound healing, and postoperative recovery |
| EP3894014A4 (en) * | 2018-12-13 | 2022-04-20 | Development Center for Biotechnology | Anti-human csf-1r antibody and uses thereof |
| EP3935391B1 (en) * | 2019-03-05 | 2024-04-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Biomarkers for renal cell carcinoma |
| WO2020232051A1 (en) * | 2019-05-15 | 2020-11-19 | Biosion Inc. | Antibody binding csf-1r and use thereof |
| AU2020283742A1 (en) * | 2019-05-24 | 2021-09-16 | Elixiron Immunotherapeutics (hong Kong) Limited | Anti-CSF1R antibodies, IL10 fusion proteins, and uses thereof |
| CN110499295A (zh) * | 2019-09-11 | 2019-11-26 | 宝船生物医药科技(上海)有限公司 | 一种csf-1r报告基因细胞株及其制备方法和应用 |
| CN114430747B (zh) | 2019-09-26 | 2025-02-25 | 豪夫迈·罗氏有限公司 | 抗csf-1r抗体 |
| AU2020366222B2 (en) * | 2019-10-17 | 2024-10-10 | National Health Research Institutes | Use of succinate as biomarker in diagnosis and treatment of cancers |
| EP4051321A4 (en) | 2019-10-30 | 2023-11-22 | Duke University | IMMUNOTHERAPY WITH COMBINATION THERAPY INCLUDING AN IMMUNOTOXIN |
| EP4073100A4 (en) | 2019-12-09 | 2024-02-14 | Syndax Pharmaceuticals, Inc. | ANTIBODIES FOR TREATING CHRONIC GRAFT VERSUS HOST DISEASE |
| KR102373965B1 (ko) * | 2020-06-05 | 2022-03-15 | (주)지아이이노베이션 | Ｉｌ-２ 단백질 및 ｃｄ８０ 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물 |
| CN115806626B (zh) * | 2022-06-21 | 2024-02-23 | 四川大学华西医院 | 一种基于csf1的嵌合抗原受体免疫细胞制备及其应用 |
| KR20260013464A (ko) | 2023-05-17 | 2026-01-28 | 신닥스 파마슈티컬스, 인크. | 항-콜로니 자극 인자 1 수용체 항체를 이용한 만성 이식편대숙주 질환-관련 폐쇄성 세기관지염 증후군의 치료 방법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IL89489A0 (en) | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
| WO1989009622A1 (en) | 1988-04-15 | 1989-10-19 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
| ES2070172T3 (es) | 1988-04-16 | 1995-06-01 | Celltech Ltd | Procedimiento para producir proteinas mediante adn recombinante. |
| JPH0967400A (ja) | 1995-08-31 | 1997-03-11 | Toray Ind Inc | モノクローナル抗体、該抗体を産生するハイブリドーマ及びその利用 |
| DE60332483D1 (de) * | 2002-11-15 | 2010-06-17 | Novartis Vaccines & Diagnostic | Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust |
| ES2569409T3 (es) | 2005-03-08 | 2016-05-10 | Pfizer Products Inc. | Composiciones de anticuerpo anti-CTLA-4 |
| PL2188313T3 (pl) * | 2007-08-21 | 2018-04-30 | Amgen, Inc. | Białka wiążące ludzki antygen c-fms |
| BRPI0909044B8 (pt) * | 2008-03-14 | 2021-05-25 | Transgene Sa | anticorpo que se liga especificamente ao csf-1r humano,composição farmacêutica e uso dos mesmos |
-
2011
- 2011-03-21 AR ARP110100905A patent/AR080698A1/es unknown
- 2011-03-22 JO JOP/2011/0097A patent/JO3291B1/ar active
- 2011-03-25 TW TW100110442A patent/TWI402078B/zh not_active IP Right Cessation
- 2011-03-28 ES ES11713416.3T patent/ES2640909T3/es active Active
- 2011-03-28 DK DK11713416.3T patent/DK2552966T3/da active
- 2011-03-28 CN CN201180017294.3A patent/CN102834414B/zh not_active Expired - Fee Related
- 2011-03-28 MX MX2012011234A patent/MX2012011234A/es active IP Right Grant
- 2011-03-28 RS RS20170817A patent/RS56219B1/sr unknown
- 2011-03-28 AU AU2011232850A patent/AU2011232850B2/en not_active Ceased
- 2011-03-28 SG SG2012064135A patent/SG183829A1/en unknown
- 2011-03-28 CA CA2795081A patent/CA2795081C/en not_active Expired - Fee Related
- 2011-03-28 UA UAA201210763A patent/UA111818C2/uk unknown
- 2011-03-28 EP EP16196811.0A patent/EP3156419A1/en not_active Withdrawn
- 2011-03-28 SI SI201131235T patent/SI2552966T1/sl unknown
- 2011-03-28 EA EA201270732A patent/EA021600B1/ru not_active IP Right Cessation
- 2011-03-28 PT PT117134163T patent/PT2552966T/pt unknown
- 2011-03-28 HU HUE11713416A patent/HUE036379T2/hu unknown
- 2011-03-28 PL PL11713416T patent/PL2552966T3/pl unknown
- 2011-03-28 LT LTEP11713416.3T patent/LT2552966T/lt unknown
- 2011-03-28 EP EP11713416.3A patent/EP2552966B1/en active Active
- 2011-03-28 NZ NZ602621A patent/NZ602621A/en not_active IP Right Cessation
- 2011-03-28 ME MEP-2017-174A patent/ME02806B/me unknown
- 2011-03-28 JP JP2013502691A patent/JP5767310B2/ja not_active Expired - Fee Related
- 2011-03-28 WO PCT/US2011/030148 patent/WO2011123381A1/en not_active Ceased
- 2011-03-28 US US13/073,004 patent/US8263079B2/en not_active Expired - Fee Related
- 2011-03-28 KR KR1020127025707A patent/KR101439719B1/ko not_active Expired - Fee Related
- 2011-03-28 HR HRP20171153TT patent/HRP20171153T1/hr unknown
- 2011-03-28 BR BR112012024564A patent/BR112012024564A2/pt not_active Application Discontinuation
-
2012
- 2012-09-14 ZA ZA2012/06926A patent/ZA201206926B/en unknown
- 2012-09-27 IL IL222222A patent/IL222222A/en not_active IP Right Cessation
-
2017
- 2017-09-07 CY CY20171100949T patent/CY1119324T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2552966T3 (da) | Antistoffer mod csf-1r | |
| US20230056881A1 (en) | TARGETED TGFß INHIBITION | |
| CN108290953B (zh) | 抗pd-1抗体和组合物 | |
| CN109715671B (zh) | 双特异性抗her2抗体 | |
| US8071099B2 (en) | Anti-FLT3 antibodies | |
| KR102770962B1 (ko) | Cd38 단백질 항체 및 이의 용도 | |
| CN109195626B (zh) | 结合死亡受体4和死亡受体5的抗体 | |
| KR20230118128A (ko) | 인터루킨-22에 대한 항체 | |
| RU2776795C2 (ru) | Антитела к белку cd38 и их применение | |
| HK40064486A (en) | TARGETED TGFβ INHIBITION | |
| HK40091337A (zh) | 针对白介素-22的抗体 | |
| HK40089052A (zh) | 特异性增强的双特异性抗体(seba) | |
| HK1176626B (en) | Antibodies against csf-1r | |
| HK1176626A (en) | Antibodies against csf-1r |